Skip navigation

News & Updates

BPGbio, Inc. acquired substantially all of the assets of Berg, LLC, and licenses from Berg, LLC the use of the Berg and Berg Health names.

Sign up here to receive news updates via email.

  • April 5, 2024 | Media, News and Updates, Press Releases

    BPGbio Presents Key Advances in its Oncology Pipeline related to the NAi Interrogative Biology Platform

    BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico. The company will present four posters showcasing these research collaborations and provide updates on other internal research activities at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, Calif.

    read more
  • February 22, 2024 | Media, News and Updates

    Pushing the frontier of drug discovery with the world’s most powerful supercomputer

    Oak Ridge National Laboratory’s Frontier, the world’s first exascale supercomputer with its dizzying 1.1 exaflop speed, is a game-changer for scientific domains ranging from drug discovery to material science and oceanography.

    read more
  • February 21, 2024 | Media, News and Updates, Press Releases

    Lincoln Property Company, BPGbio, and Cresa Announce 70,000-sq.-ft. Lease at 300 Third Avenue in Waltham 

    Lincoln Property Company (“Lincoln”), Cresa Boston, and BPGbio, Inc, a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that BPGbio has leased approx. 70,000 sq. ft. of lab and office space at 300 Third Avenue in Waltham, Mass. The company plans to relocate its headquarters from Framingham and expand into two full floors of the new space circa June 2025, significantly increasing its footprint in the Boston region.

    read more
  • January 21, 2024 | Media, News and Updates, Press Releases

    BPGbio Appoints Ritesh Srivastava as General Counsel

    BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the appointment of Ritesh Srivastava as General Counsel. In this role, Mr. Srivastava will lead legal and compliance functions for the company as it grows its therapeutics and diagnostics businesses through R&D and new development and commercial partnerships. 

    read more
  • January 20, 2024 | News and Updates, Media

    Supercomputer-based Bayesian approach to AI pays dividends for BPGbio

    In an AI hype-filled biopharma industry, one company is taking a back-to-basics yet supercomputer-powered approach — using Bayesian analysis on massive patient datasets to guide drug discovery.

    read more
  • January 17, 2024 | Media, News and Updates, Press Releases

    BPGbio Presents Updated Phase 2a Clinical Results Demonstrating Benefit of BPM31510 in Combination with Chemotherapy in Pancreatic Cancer at ASCO GI

    BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today will announce new data from a phase 2a clinical trial of its lead candidate, BPM31510, in patients with advanced pancreatic cancers at the annual ASCO Gastrointestinal Cancers Symposium, being held January 18-20, 2024, in San Francisco, Calif.

    read more